ArticleFrontiers in pharmacology2022
Cost-effectiveness analysis of adebrelimab combined with chemotherapy for extensive-stage small cell lung cancer.
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cost-effectiveness of the combination of immunotherapy and chemotherapy for extensive-stage small-cell lung cancer: a systematic review.BMC health services research · 2023Pooled it
- Cost-Effectiveness Analysis of Anlotinib Plus Penpulimab Versus Sorafenib in the First-Line Treatment of Unresectable Hepatocellular Carcinoma in China.Clinical drug investigation · 2026Article
- Economic evaluation of finotonlimab plus bevacizumab as first-line therapy for advanced hepatocellular carcinoma.PloS one · 2026Article
- Cost effectiveness and pricing strategy of first line benmelstobart combination treatment for extensive stage small cell lung cancer in China.Scientific reports · 2025Article
- Cost-effectiveness of benmelstobart-anlotinib-chemotherapy in extensive-stage small-cell lung cancer: A comparative analysis across United States and Chinese healthcare systems.International journal of clinical pharmacy · 2025Article
- Cost-effectiveness of benmelstobart and anlotinib plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer in China.Scientific reports · 2025Article
- Cost-effectiveness evaluation of benmelstobart, anlotinib and chemotherapy in patients with extensive-stage small-cell lung cancer.Frontiers in pharmacology · 2025Article
- Article
- Updated cost-effectiveness analysis of adebrelimab plus chemotherapy for extensive-stage small cell lung cancer in China.BMJ open · 2024Article
- Cost-effectiveness of first-line versus second-line use of brigatinib followed by lorlatinib in patients with ALK-positive non-small cell lung cancer.Frontiers in public health · 2024Article
- Progress of research on PD-L1 inhibitor adebrelimab usage in malignant tumors.Frontiers in oncology · 2024Review
- Adebrelimab plus chemotherapy vs. chemotherapy for treatment of extensive-stage small-cell lung cancer from the US and Chinese healthcare sector perspectives: a cost-effectiveness analysis to inform drug pricing.Frontiers in pharmacology · 2023Article
- Cost-effectiveness analysis of first-line serplulimab combined with chemotherapy for extensive-stage small cell lung cancer.Frontiers in public health · 2023Article
- Cost-effectiveness analysis of serplulimab combination therapy versus chemotherapy alone for patients with extensive-stage small cell lung cancer.Frontiers in oncology · 2023Article
- The cost-effectiveness of cemiplimab plus chemotherapy as the first-line treatment for advanced non-small cell lung cancer.Frontiers in pharmacology · 2023Article
- Cost-effectiveness of serplulimab as first-line therapy for extensive-stage small cell lung cancer in China.Frontiers in immunology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.